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ABSTRACT the investigation of marine natural products (low molecular weight bioregulators) is a rapidly developing scientific field at the intersection of biology 
and chemistry. Investigations aimed at detecting, identifying, and understanding the structure of marine natural products have led to the discovery of 20,000 new 
substances, including those characterized by an extremely high physiological activity. Some results and prospects of works aimed at creating new drugs on the 
basis of marine natural products are discussed herein. 
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INTRODuCTION
Low molecular natural products are largely referred to the 
so-called secondary metabolites. In contrast to primary me-
tabolites, these substances are rare in occurrence and may be 
detected only in some taxa, and occasionally, in one biological 
species (subspecies, strain). they are formed on the basis of 
precursor substances participating in primary metabolism, 
such as acetic acid, amino acids, glucose and are observed 
mainly as final products of biochemical transformations. Sec-
ondary metabolites are quite diverse by chemical structure 
and include steroids, terpenoids, alkaloids, polyketides, phe-
nolic metabolites, some carbohydrates, lipids, and peptides. 
Оn the other hand, secondary metabolites can be classified 
on the basis of their biological functions as hormones, anti-
biotics, toxins, pheromones, etc. Among the natural products 
there are endo-metabolites, i.e., substances exercising their 
biological functions in the organisms-producers, for instance, 
oxylipins, hormones, phytoalexins, and more numerous ex-
ometabolites released into the environment and being of eco-
logical importance, including toxins, antibiotics, and different 
signal compounds. 
the higher terrestrial plants and soil microorganisms were, 
for a long time, considered to be the major biological sources 
of natural products. However, when skin-diver equipment 
was invented and became widely used, different marine or-
ganisms began also to be referred to their sources. the study 
of marine organisms significantly increased the amount of 
known natural products. In fact, the total number of studied 
natural products is unlikely to exceed 120-150 thousands, and 
by the estimates of many scientists, the amount is even lower 
[1], whereas about 20 thousand natural substances have been 
segregated. Moreover, the first researchers were surprised by 
the fact that marine organisms very rarely contained already 
known compounds. Hence, the biochemistry of their second-
ary metabolism differs substantially from that of terrestrial 
organisms. this fact may be explained by significant taxo-
nomic differences between terrestrial and marine animals, 
plants and microorganisms. 
As a whole, the investigation of natural products is of eco-
logical importance. It stimulates the development of organic 
synthesis, physicochemical and isolation methods, as well as 
other sciences, such as biochemistry, molecular genetics, bio-
technology, and microbiology. Moreover, it is closely related 
to healthy diet. 
natural products have played and continue to play an im-
portant role in the creation of new drugs and development 
of the pharmaceutical industry around the world. Analge-
sic preparations based on morphia from opium, cardioactive 
digitalis glycosides, anti-inflammatory agents created in the 
course of the investigation of steroid hormones, antibiotics, 
and many others are included in a list of products devel-
oped on the basis of natural drugs or their derivatives and 
analogues, which contains about 50% of all currently known 
medical products [5].
results of the investigation of marine natural products 
which have been used or are being used now for the creation 
of new drugs are considered herein. 
MARINE NATuRAL PRODuCTS WITh ANTITuMOR PROPERTIES .
With the use of an aqualung, natural-product chemists got 
a chance to study more and more marine organisms. the 
American scientist Werner Bergmann was one of the first 
to start their chemical investigation. In 1951, he reported the 
isolation of unusual nucleosides (spongothymidine (1) and 
spongouridine (2) (Fig. 1), and then others) [2-4] from the 
sponge Cryptotethia crypta collected near the coast of Florida. 
they contained arabinose residues, instead of the ribose and 
desoxyribose residues observed in most compounds of that 
class. those investigations stimulated the appearance of the 
antimetabolite conception in pharmacology. Antimetabolites 
are the active substances of drugs, which are characterized 
by a significant similarity to, and structural difference from, 
human metabolites. Antimetabolites participate in the biosyn-
thesis of some biopolymers, more often, of DnA, and inhibit 
its exhibiting antitumor and antiviral properties. Bergmann’s 
discovery was followed by the development of two arabino-16 | ActA nAturAe |  № 2 2009
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nucleoside drugs: arabinoadenine (3) (ara-A, Vidarabine) and 
arabinocytosine (4) (Ara-c, cytarabine) (Fig. 1), which were 
used in clinical practice as antitumor and antiviral drugs for 
tens of years. Several other drugs of a nucleoside nature (azi-
dothymidine, acyclovir, etc.) differ from ordinary nucleosides 
in other structural features. For instance, azidothymidine has 
an azide group in its monosaccharide residue, while acyclovir 
is characterized by an open furanose cycle.
However, further development of antitumor drugs on the 
basis of marine natural products was not just so successful. 
the case was not that there were no compounds with high 
antitumor activity. On the contrary, some marine inverte-
brates had minor secondary metabolites characterized by 
extremely high toxicity against tumor cells. By their cyto-
toxicity, they are hundreds and thousands of times superior 
to most active antitumor drugs currently in use. For instance, 
spongistatin (5) (Fig. 2) from marine tropic sponges is the most 
active of all natural and synthetic compounds found over the 
history of the investigation of antitumor compounds at the 
national Institute of cancer (uSA). It was initially found in 
one of the sponges, owing to the biological activity of the cor-
responding extracts, but for a long time the compound itself 
could not be obtained in the amount required for a structural 
investigation. Only after the collection and processing of three 
tones of sponge did the scientists finally manage to obtain 0.8 
mg of spongistatin. then, another sponge collected near the 
Maldive Islands was used as a basic material, and after the 
processing of 400 kg of this sponge, the scientists obtained 
another 10 mg of spongistatin, shed light on its structure, and 
began analyzing the physiological action of that macrolide. 
the inhibitory dose needed to cause the death of 50% of tu-
mor cells (Ic50) was 10-10 М for colon cancer cells and 10-12 М 
for breast cancer cells. In experiments on animals with deadly 
malignant tumors, 70% of them survived after the injection of 
25 μg/kg of spongistatin. 
As a whole, several dozens of marine metabolites, ex-
tremely toxic against tumor cells, were detected. It is very 
important that many of them belong to the fundamentally 
new structural series of antitumor substances that opens good 
prospects for synthetic modeling. until those substances were 
discovered, all of the natural products applied in chemothera-
py were referred to not more than 4-5 structural types. 
However, the creation of new-generation medical products 
based on marine natural products is being slowed down by 
some complicated issues. Firstly, these substances are diffi-
cult to access. It is impossible to harvest a sufficient amount of 
these substances from marine organisms, because their pro-
ducers, as a rule, are rare and disseminated species, while the 
methods for aquaculture of such biological products remain 
poorly developed. economically, reasonable syntheses for most 
of these substances have yet to be developed as well, due to the 
complexity of their structures and abundance of asymmet-
ric centres in them. Secondly, these compounds, highly toxic 
against tumor cells, do not always demonstrate good antican-
cer activity when we are dealing with people or animals. And, 
thirdly, some of them are characterized by side effects; for in-
stance, they can negatively affect kidneys or other organs and 
systems, which excludes their clinical application.  
nevertheless, development of another antitumor drug 
based on marine natural products was successfully completed 
just recently. In the end of 2007, the drug trabectidin (Yon-
delis) was approved in european union countries for treat-
ment of soft tissue sarcoma. the structure of the correspond-
ing active substance, alkaloid ecteinascidin-743 (et-743) (6) 
(Fig. 1) from the ascidian Ecteinascidia turbinata, was eluci-
dated independently by two groups of American scientists 
18 years ago [7, 8]. However, the high antitumor activity of 
extract E. Turbinate had been known long before their dis-
covery, since 1969. the toxic concentration of that substance 
(IС50) against the tumor cells L-1210 was very low (0.5 ng/ml), 
and in microgram doses (per one kg of test animal weight) 
it demonstrated a high antitumor activity against different 
types of mouse cancer. 
Multi-stage total syntheses of that substance could not 
provide researchers with a sufficient amount of material for 
bioassay. For instance, the total yield in the first such syn-
thesis was less than 1% [9]. As a result, methods of ascidian 
cultivation were developed, and submarine plantations were 
created near the coast of Spain. However, that method of pro-
duction of the basic biological material was also rather inap-
propriate due to significant variations in the content of ectei-
nascidins, which were used in clinical testing, in the ascidians 
cultivated. Finally, after long research, scientists managed to 
obtain this alcaloid by chemical transformations from antibi-
otic cyanosafracin B, which is produced with a good yield by 
the terrestrial bacterium Pseudomonas fluorescens [10].
the mechanism of biological action of the trabectidin ac-
tive substance, ecteinascidin-743, on tumor cells is related 
to its ability to penetrate the DnA’s minor groove and to 
alkylate guanine residues [11]. Moreover, trabectidin causes 





Fig. 1. Antitumor and antiviral drugs created on the basis of marine 
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programmed death (apoptosis) of tumor cells and intensifies 
the antitumor action of some well-know drugs (doxorubicin, 
paclitaxel (taxol), etc.). In spite of the fact that trabectidin 
was approved only for the treatment of soft tissue sarcoma, 
it showed good results in the course of clinical testing for the 
treatment of other types of malignant tumors. not long ago, 
the Pharmamar company (Spain) that has created trabec-
tidin sold the license to Jonhson&Jonhson/Ortho Biotech to 
promote that drug on the American market.
A series of other marine natural products possessing ex-
tremely high cytotoxicities against tumor cells like spong-
istatin and ecteinascidin are being studied now as potential 
antitumor drugs and are subject to different stages of clinical 
and preclinical testing [12, 13] (table 1). 
For instance, bryostatin-1 (7) (Fig. 2), the 26-membered 
macrocyclic lactone from the bryozoan Bugula neritina, a 
fouling organism that grows in thick colonies on pier pilings 
and docks in the World Ocean, was detected by Pettit and 
co-workers from Arizona State university after several sam-
plings of the biological material. Its structure was elucidated 
with the help of X-ray analysis. the compound (7) has 11 
asymmetric centres, and it is hardly probable it will be ob-
tained with a sufficient yield by organic synthesis in the years 
to come. Its content in bryozoan is insignificant (0.00001%), 
but scientists have managed to obtain 18 g of bryostatin for 
clinical and preclinical testing from 10,000 gallons of bryo-
zoan collected. this substance has been determined to be a 
modulator of protein kinase c, a stimulator of the immune 
system, and an inductor of cell differentiation. It intensifies 
the antitumor action of some drugs but causes myalgias as a 
side effect. currently, this drug is being tested in combination 
with paclitaxel, vincristine, ara-c, etc. (table 1).
Dolastatin 10 (8) (Fig. 2) was discovered after an expedi-
tion by Professor Pettit to the Mauritius Island in 1972, when 
they collected the marine nudibranch Dolabella auricularia 
and discovered the high antitumor activity of its extracts. 
to obtain the first milligram of the extract’s active compo-
nent – compound (8) – the scientists had to collect again a 
giant amount of that rare mollusk (about 2 tones) due to a low 
content of the required substance. Dolastatin 10 appeared 
to be a linear pentapeptide with residues of four previously 
unknown amino acids: n,n-dimethylvaline, dolaisoleucine, 
dolaproine, and dolaphenine [14]. In 1989, researchers car-
ried out a total synthesis of that peptide, which confirmed 
the structure suggested and established its absolute stereo-
chemistry [15]. Dolastatin 10 is extremely toxic against tumor 
cells, and its semitoxic concentration (IС50) against cells of 
limphocytic leukemia P388 is 4.5x10-5 μg/ml. However, at the 
first and second stages of clinical testing its high antitumor 
activity was not confirmed. A while ago, the clinical testing of 
dolastatin was discontinued. 
On the other hand, attempts to create a dolastatin-based 
antitumor drug were not abandoned. It has been discovered 
that the synthetic dolastatin derivative tZt-1027, in which 
the dolaphenine aminoacid is replaced with the phenylalanine 
group, just like dolastatin, is a strong inhibitor of tubulin po-
lymerization, stops the division of cancer cells in very low 
concentrations, and reduces blood supply to tumors (inhibits 
angiogenesis). currently, tZt-1027 (soblidotine) is under-
going clinical testing in Japan, europe, and the uSA for the 
treatment of solid tumors, including those resistant to other 
drugs [16].
Hemiasterlin (9) (Fig. 2) is a tripeptide that was extracted 
for the first time from the deep-water sponge Hemiastrella 
minor by Kashman and his co-workers in 1986 [17]. Its syn-
thetic analogue HtI-286, with a phenyl substituent instead of 
n-methylindol, appeared to be more active and, in nanomo-
lecular concentrations, inhibited cell division binding with the 
monomeric units of tubulin and complicating its polymeriza-
tion [18]. In preclinical testing, it showed good activity against 
tumors resistant to paclitaxel, one of the best antitumor drugs 
used currently. However, the clinical testing did not confirm 
that it was active in the case of patients in terminal stages 
of cancer. recently, scientists demonstrated the antitumor 
action of this drug on androgen-dependent tumors, which 
has inspired renewed interest in further clinical studies of 
HtI-286 [19].
Discodermolide (10) (Fig. 3) was isolated by scientists of 
the Harbor Branch Oceanographic Institute (Florida, uSA) 
from the rare deep-water sponge Discodermia disollata col-
lected in the Bahamas at depths of up to 300 m using a sub-
marine. the chemical structure of the compound (10) was 
elucidated with the help of a thorough analysis of nMr spec-
tra and X-ray analysis, and it was confirmed by syntheses of 
discodermolide itself [22] and its antipode (-)-discodermolide 
[21], which in contrast to the natural (+)-isomer appeared to 
be much less active as a potential antitumor agent. Actually, 
natural discodermolide was able to stop the development of 
tumor cells at the G2/M phase of the cell cycle in concen-
trations of 3-80 nM, whereas the (-)-isomer was 2-20 times 
weaker. the drug appeared to be a much stronger inhibitor of 
tubulin polymerizations than paclitaxel; moreover, their com-
bined action was stronger than the action of each one of those 
5 Spongistatin
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agents. After multiple improvements of different variants of 
the multistage discodermolide syntheses, researchers of the 
pharmaceutical company novartis managed, finally, to ob-
tain 20g of that substance, to complete its preclinical testing 
in 2004-2005, and to start clinical testing. to date, this test-
ing has been discontinued. In spite of the fact that this drug 
is relatively low-toxic for patients, it remains insufficiently 
effective. nevertheless, it may be used in combination with 
other antitumor drugs [13]. 
tubulin-binding agents also include cryptophycins and 
related compounds. cryptophycins are depsipeptides pro-
duced by cyanobacteria Nostoc spp. [23]. they got their name 
for strong inhibitory activity against the pathogenic bacteria 
Cryptococcus spp. However, their antitumor properties have 
attracted even more attention. For instance, cryptophycin-1 
(11) (Fig. 3) is toxic against tumor cells in concentrations of 
1-10 pg/ml. complete synthesis of cryptophycin-1 [24] has 
made it possible to pinpoint its structure and allowed the 
eli Lilly company to start the creation of a cryptophycin-
based antitumor drug. In particular, a synthetic analogue of 
cryptophycin-1, the so-called cryptophycin-52, has proved 
more active against tumor cells than vinca peptides and pa-
clitaxel by 40 and 400 times, respectively. However, in clini-
cal testing it has appeared to be highly toxic for patients. 
testing had to be stopped in the end of the 1990s. Later, new 
derivatives – cryptophycin-309 and -249 – were obtained, 
which are now undergoing the final stage of preclinical test-
ing [13].    
Several highly active depsipeptides from ascidians, includ-
ing didemnin B from Trididemnium solidum [25], were in-
tensely studied for many years as potential antitumor drugs. 
However, in the mid 1990s, the clinical investigations of di-
demnin B were discontinued due to significant neuromus-
cular toxicity and insufficient effectiveness for patients in 
terminal stages of cancer. However, its analogue aplidin (12) 
(dehydrodidemnin B) (Fig. 3) from the Mediterranean ascid-
ian Aplidium albicans initiates oxidative stress with the fol-
lowing apoptosis in tumor cells [26]. Aplidin is also an inhibitor 
of angiogenesis and disturbs blood supply to tumors. In spite 
of the fact that aplidin is at the second stage of clinical testing 
as a drug for myeloma treatment, a good method to produce 
it has not been developed yet, because neither the technology 
for the corresponding ascidian cultivation, nor an appropri-
ate synthesis for the production of a sufficient amount of this 
substance have been elaborated [13].  
In 1986, uemura and Hirata isolated several minor me-
tabolites called halichondrins from the sponge Halichon-
dria okadai [27]. those compounds were strong inhibitors 
of tumor cell development (IС50 10-9 М), bound to tubulin 
on the same site as the vinca peptides applied in clinical 
treatment, and were selected for the further investigation 
of their antitumor properties. However, it was rather dif-
ficult to produce halichondrins in sufficient amount. Due to 
a complex structure, the total synthesis of halichondrin B 
developed in 1992 [28] consisted of 90 stages and could not 
solve that problem. Almost at the same time, new Zealand 
Table 1. Certain marine natural compounds are potential anticancer drugs 
Compound Biological Source Chemical nature Mechanism of action Company Status
Bryostatin-1 (7) Bryozoan Polyketide Inhibits a protein 
kinase GPc Biotech Phase II clinical trials
Dolastatin-10 (8) Mollusc Peptide Inhibits microtubule 
formation ncI-Knoll Phase II clinical trials of 
the derivative tZt-1027
HtI286 (9) Sponge tripeptide Inhibits microtubule 
formation novartis continuing clinical trials
Discodermolid (10) Sponge Polyketide Inhibits microtubule 
formation novartis Phase II clinical trials
cryptophycin (11) cyano-bacterium cyclic depsipeptide Inhibits microtubule 
formation eli Lilly removed from phase II 
clinical trials
Aplidin (12) Ascidium cyclic depsipeptide causes oxidative stress 
in cells PharmaMar Phase II clinical trials
eribulin mesylate (13) Sponge Polyester derivative  Inhibits microtubule 
formation esai company Phase III clinical trials
Squalamine (14) Shark Steroid Inhibits angiogenesis Genaera removed from phase II 
clinical trials
Kahalalide F (15) Mollusc cyclic depsipeptide Lysosome-tropic  
effect PharmaMar Phase II clinical trials
Salinosporamide А 
(16) Marine bacterium Lactam-lactone 
derivative Proteasome inhibitor  nereus Phase II clinical trialsreVIeWS
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scientists discovered new source of halichondrins, the deep-
water sponge Lissodendoryx n. sp.1. A ton of that sponge 
was obtained by dredging. Moreover, plantations of Lisso-
dendoryx were created in shallow waters in new Zealand, 
though the content of the target agents was much lower in 
the cultivated tube than in the wild one [29]. those efforts 
made it possible to obtain 310 mg of halichondrin B and to 
begin clinical testing in 2002. then, Japanese scientists, in 
collaboration with the esai company, found out that a much 
simpler derivative of halichondrin – eribulin mesylate (13) 
(Fig. 3) –was characterized by the same biological activity. 
currently, eribulin mesylate is in the third stage of clinical 
testing as a potential drug for the treatment of breast cancer 
[13]. Moreover, it is being tested for the treatment of pros-
tate cancer and sarcoma. 
Squalamine (14) (Fig. 3), a water-soluble aminosteroid, 
was extracted from the liver of the shark Squalus acanthis in 
1993. this substance displays strong antimicrobial action [30, 
31]. Later, using different types of mouse cancer, squalamine 
was found to inhibit angiogenesis and to stop the growth of 
tumors [32]. the Genaera company organized pharmacologi-
cal investigations of squalamine, but at the second stage of 
clinical testing (pulmonary and ovarian cancers), its antitu-
mor properties were found to be insufficient. nevertheless, 
squalamine was found to intensify the therapeutic effect of 
paclitaxel and carboplatin, inhibiting some growth factors, 
for instance VeGF, and causing a decrease in the amount of 
blood vessels around the tumor and apoptosis of tumor cells. 
Moreover, it was established that its physiological effects 
could be useful in the treatment of diseases characteristic of 
elderly people and related to vision disorders (macular degen-
eration) [33, 34].  
the investigation of the mollusc Elysia rufescens under the 
guidance of Scheuer at the Hawaiian university in the uSA 
led to the discovery of several new high-active depsipeptides, 
including kohalalide F (15) (Fig. 4) [35]. this mollusc feeds on 
the algae Bryopsis spp., the real producers of kohalalide. the 
mollusc accumulates this biologically active substance as a 
chemical protective means against predators. Moreover, the 
kohalalide content in the mollusc is 5,000 times higher than 
in the algae. After the solid-phase synthesis of that peptide, 
its structure and relative stereochemistry were corrected [36] 
and the PharmaMar company began the preclinical and then 
clinical investigation. 
Kohalalide induces the formation of vacuoles in some tu-
mor cells and stimulates lysosomes. It is several times more 
toxic against tumor cells than against healthy cells [37]. In 
spite of the fact that the mechanism of the kohalalide’s anti-
tumor action has yet to be pinpointed , currently, it is in the 
second stage of clinical testing for the treatment of solid tu-
mors resistant to other substances [13]. 
Salinosporamide A (16) (Fig. 4) was isolated in 2003 by 
Fenical and co-workers (Scripps Institution of Oceanography, 
california, uSA) from the salt-tolerant marine bacterium re-
ferred to as a new class of bacteria-actinomycetes called Sa-
linispora [38]. It inhibits p26 proteosomes [36]. not long ago, 
the pharmaceutical company nereus Pharmaceuticals (uSA) 
completed the first stage of clinical testing of that substance 
coded as nPI-0052 for the treatment of multiple myeloma 
[13]. 
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In addition to the above-mentioned substances, several 
other marine natural products have been clinically studied as 
potential antitumor agents: peptide cematidine from moluscs, 
peptide ILX-65 similar to dolastatin, and tripeptide e-7974 
from the sea sponge inhibiting polymerization of tubulin [5, 
13, 40] (Knoll company); derivative of aminoacid LAF389 be-
ing an inhibitor of methionine-aminopeptidase (novartis); 
synthetic analog of sponge cerebroside Krn7000 character-
ized by immunostimulatory and strong antitumor action on 
patients who retained a high level of nK cells. Prospects for 
the further clinical study of these substances are unclear. 
In russia, alkaloids – polycarpin (17) (Fig. 4) [41] and var-
acin c (18) [42], characterized by high toxicity against tumor 
cells, were isolated from ascidians. cytotoxicity and activ-
ity in the acid environment of varacin c (18) are higher than 
those of well-known doxorubicin: that is why varacin is quite 
selective as regards tumors, in comparison to normal tissues 
[43]. In fact, some tumors are known to acidify themselves 
due to elevated glycolysis. Polycarpin and its numerous syn-
thetic analogues cause apoptosis of tumor cells, intensifying 
the phosphorylation of protein p53 at the aminoacid residue 
Ser-15 [44]. However, they have appeared to be rather toxic 
to animals. Varacin c was synthesized shortly after isolation 
[43], and a while ago, in russia, scientists began the synthesis 
of its analogues and obtained several high-active compounds 
promising for further investigation as pharmaceutical leads 
[45]. 
Hence, most of the substances selected for preclinical and 
clinical testing are strong inhibitors of tubulin polymeriza-
tion. Moreover, they include inhibitors of protein kinase С 
(bryostatin), other enzymes (LAF-389), inhibitors of prote-
osomes (nPI-0052), agents interacting with DnA (Yondelis), 
inhibitors of angiogenesis (aplidin, kohalalide, and squala-
mine), and substances with an undetermined mechanism of 
action. taking into consideration the wide diversity in the 
structures of highly active marine metabolites and the dif-
ferent mechanisms through which they exhibit antitumor 
action, there is confidence that further efforts aimed at creat-
ing antitumor drugs on the basis of marine natural products 
will be successful. 
MARINE NATuRAL PRODuCTS WITh ANALgESIC PROPERTIES
the first analgesic drug based on marine natural products 
was called ziconotide (prialt). It was created after twenty 
years of investigating toxins from predatory moluscs-gas-
tropods belonging to the Conus genus. In the end of 2004, this 
compound under the commercial name “prialt” was approved 
for production and clinical use in the uSA, and a few months 
later, in europe. the name “ziconotide” is more often used 
for its active substance, ω-conotoxin, obtained with the help 
of peptide synthesis. 
cone snails, more than 300 species are known, use small 
fish for food, which snails catch by a harpoon connected by a 
special channel to their poison gland. the snails’ glands bio-
synthesize hundreds of different peptide toxins [46], which 
immobilize a victim by affecting the neuromuscular trans-
mission in its organism. 
understanding of the structure of some toxins from dif-
ferent species of cone snails was followed by the synthesis 
of thousands of their analogues. However, pharmacological 
trials showed that one of the natural toxins, rather than their 
synthetic derivatives, was of top interest as a potential drug. 
that toxin was named ω-conotoxin МVIIA. ω-conotoxin is 
a linear peptide composed of 25 aminoacid residues, which 
was isolated for the first time from the Pacific mollusc Conus 
magnus. Six cysteine residues form three disulphide bridges 
in this compound [47, 48]. the disulphide bridges provide 
ω-conotoxin with a well-formed and unique space struc-
ture, as well as the ability to specifically block the work of 
n-type voltage-sensitive calcium channels. As a result, the 
toxin efficiently inhibits the transmission of the pain signal 
(Кd=9 pM). clinical investigations of synthetic ω-conotoxin 
were carried out by the pharmaceutical company neurex 
(branch elan Pharmaceuticals). As an analgesic it appeared 
to be 1,000 times stronger than morphine [49]. those inves-
tigations showed its high efficiency in the inhibition of pain, 
including phantom ones. In contrast to morphine, ziconotide 
(19) (Fig. 5) did not cause hallucinogenic effect and addicting 
property effect and does not cause addiction [50]. 
Several other conotoxins are now at different stages of 
investigation as potential drugs. clinical trials of some com-
pounds of that class were discontinued due to undesirable 
side effects: for instance, the AM-336 peptide-based drug, 
which was developed by the AMrAD company for the treat-
ment of chronic pains.  
15  Kahalalide F
16 Salinosporamide A 17  Polycarpine
18 Varacin C
Fig. 4. Some compounds investigated as active substances of antitumor 
drugsreVIeWS
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recently discovered groups of conotoxins, which specifi-
cally block α1−adrenoreceptors, are good model compounds 
for the creation of new analgesic medical products on their 
basis [51]. 
ANTI-INFLAMMATORY AND WOuND-
hEALINg MARINE NATuRAL PRODuCTS
Pseudopterosins, for instance pseudopterosin e (20) (Fig. 5), 
are characterized by strong anti-inflammatory action. Pseu-
dopterosins belong to the group of diterpene glycosides iso-
lated by Fenical and co-workers from the caribian gorgonian 
coral Pseudopterogorgia elisabethae in the end of the 1980s 
[52]. the anti-inflammatory action of pseudopterosins is 
stronger than that of the well-known anti-inflammatory drug 
indomethacin. they influence the biochemical transformation 
of arachidonic acid, decreasing the synthesis of eicosanoids 
[53]. estee Lauder has created a cosmetic cream for facial skin 
for commercial realization on the basis of partially purified 
extracts of P. elisabethae, containing pseudopterosin e. to 
ensure production of the cream with the required amount of 
pseudopterosins, scientists collected a lot of gorgonian corals 
along the coast of the Bahamas Islands and, then, studied the 
regeneration of corals after the removal of some parts of their 
colonies. two other ways to produce pseudopterosin were de-
veloped to decrease the damage to underwater biocenoses: 
their aglycons were synthesized by several methods [54-56] 
and, then, glycosylated: moreover, scientists have discovered 
new biotechnological ways to produce pseudopterosin from 
farnesol pyrophosphate under the action of enzymes extract-
ed from P. elisabethae [57]. 
the synthetic derivative of pseudopterosins called meth-
opterosin (OAS 1000) was subjected to clinical testing as an 
anti-inflammatory agent for the treatment of contact der-
matitis. However, those trials were not completed due to the 
bankruptcy of the OsteoArthritis Sciences Inc. company [34]. 
Later, that substance was subjected to the second stage of 
clinical testing as a wound-healing agent by tyrosin Group 
Inc. company (uSA). 
contignasterol (21) (Fig. 5) [58], an unusual steroid from the 
sponges Petrosia contignata, was studied under the code IZP 
94005 as an anti-inflammatory agent. the structure of contig-
nasterol is characterized by a cis-junction of the c and D cy-
cles. In contrast to drugs with analogous action, this compound 
(21) is not an inhibitor of A2 phospholipase, but it inhibits the 
excretion of histamine by leukocytes and is referred to as a 
leukocyte-selective anti-inflammatory agent [59]. Inflazyme 
Pharmaceutical Ltd. and Aventis Pharma (uSA) were jointly 
developing a new drug on the basis of contignasterol. However, 
because of its extremely complicated structure, contignasterol 
was modified and replaced with the simpler, but highly active, 
synthetic analogues IPL 576092 and IPL 512602 [60, 61]. 
this latter compound underwent two stages of clinical 
testing for the treatment of asthma. In 2004, cooperation be-
tween the two companies ended and Inflazyme chose to work 
independently: several more promising derivatives were ob-
tained, while the testing included not only asthma, but also 
skin and eye disorders [34]. However, after the sale of this 
project in 2008 to Orexo Pharmaceuticals company, infor-
mation about further investigation of the substance has not 
appeared. 
One more terpenoid – monoalide (22) (Fig. 6) – was ex-
tracted from sponges Luffariella variabilis [62] by Scheuer 
and co-workers in 1980. Monoalide has two hidden aldehy-
dic groups (hemiacetal and as a γ-lactone derivative) which 
react with the amino groups of lysine residues on the sur-
face of the substratum binding site in A2 phospholipase. As 
a result, monoalide (22) inhibits this enzyme and the hy-
drolytic elimination of arachidonic acid from prospholipide, 
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demonstrating anti-inflammatory properties. the strong 
anti-inflammatory action of monoalide [63, 64] has attracted 
the attention of Allergen Pharmaceutical company (uSA). 
the company secured a license for the drug and carried 
out two stages of clinical testing of monoalide as a drug for 
the treatment of psoriasis. However, problems with the low 
transport of the active substance through a patient’s skin 
led scientists to stop further clinical investigations. At the 
same time, monoalide is released as a biochemical reagent, 
a specific inhibitor of A2 phospholipase. Moreover, scientists 
continue to try to obtain such a derivative of monoalide that 
will be devoid of its disadvantages, with the help of organic 
synthesis. 
the Pacific Institute of Bioorganic chemistry, Far east 
Division of the russian Academy of Scientists, created a new 
drug called collagenase KK based on a complex of collageno-
lytic proteases from the Kamchatka King crab Paralithodes 
chamtschaticus. After preclinical and clinical testing, colla-
genase KK was approved for production and use in russia. 
the drug was recommended for fermentative wound cleans-
ing in case of pitting, necrosis, chilblains, gangrene, chronic 
osteomyelitis, and varicose ulcer [65-67]. experience in the 
clinical application of collagenase KK after the release of the 
first batches shows that this drug, in addition to the above-
mentioned areas of medical application, may be useful for the 
treatment of some other diseases and post-surgery complica-
tions. For instance, collagenase KK was successfully used in 
endoscopic and plastic surgery and for the treatment of foul 
peritonitis in children. collagenase KK may also be used for 
the destruction of collagen in commissures. 
MARINE NATuRAL COMPOuNDS WITh ANTIVIRAL 
AND ANTIMICROBIAL PROPERTIES .
After the discovery of arabinonucleosides characterized by 
antiviral and antitumor properties in the beginning of the 
1950s and after the following synthesis of some nucleoside de-
rivatives, which became the biologically active substances of 
antiviral drugs, the search for new marine antiviral drugs has 
been in progress. compounds with such activity were found 
among terpenoids, steroids, alkaloids, аliphatic and aromatic 
derivatives, peptides, polysaccharides, and other secondary 
metabolites extracted from different marine organisms [68-
71]. 
AIDS remains one of the most dangerous viral diseases 
affecting a great number of people. the number of people 
suffering from AIDS approximates 50 million and increases 
every day by 16 thousand people. By the early 2003, more 
than 150 highly active marine metabolites were found in the 
course of testing against HIV [69, 70]. edible algal polysac-
charides, in particular fucoidans, carrageenans, and others, 
inhibit the penetration of HIV into human mononuclear cells. 
Some of them inhibit virus replication in very low concentra-
tions (0.1-0.01 μg/ml) and intensify the antiviral action of azi-
dothymidine. However, some specialists believe that their an-
tiviral effects are the result of nonspecific interaction either 
with viruses, or with cells, while these substances themselves 
poorly penetrate biological fluids [70]. Hence, the question as 
to whether these substances can be considered as additional 
agents that in future may be used for the treatment of AIDS 
patients remains a matter of debate. 
Peptides from some marine invertebrates are one more 
perspective group of antiviral substances. For instance, pep-
tides composed of 17-18 amino-acid residues from horseshoe 
crabs Tachypleus tridentatus and Limulus polyphemus are 
characterized by strong antiviral effect against HIV-1. Analo-
gous, but simpler in structure compounds were synthesized 
in the course of a project aimed at creating a new drug on 
the basis of those peptides. One of the peptides (t144) had 
Ic50=2.6 nM against HIV-1 at low cytotoxicity (Ic50=44.6 μМ) 
[72, 73, 69]. the project aimed at creating a t144-based anti-
viral drug has a fair chance of success.   
Among the highly active low-molecular antiviral marine 
substances it is important to note the above-mentioned di-
demnin B from ascidians, which when injected every day in a 
dose of 0.25 μg/kg to mice contaminated with a lethal dose of 
rift Valley fever helped save 90% of them. Some hope is re-
lated to a relatively simple terpenoquinone avarone (23) (Fig. 
6) and similar compounds from the sponges Dysidea, which 
inhibit reverse transcriptase from HIV-1 and the virus itself 
in a concentration of 0.1 μg/ml [70]. Mycalamide В (24) (Fig. 6) 
from the new Zealand Mycale sp. may be cited as another ex-
ample of antiviral metabolite from sponges. Mycalamide В is 
a strong inhibitor of protein synthesis, which shows inhibiting 
activity in a dose of 2 ng/band when tested in vitro for action 
on different viruses [70]. the creation of drugs on the basis 
of these and other highly active compounds is slowed down 
by the high toxicity of some of them and low accessibility. 
However, these and other highly active marine substances 
are good models for syntheses of new less toxic, but highly 
active, antiviral agents. 
Some of the numerous marine antimicrobial compounds 
displayed high activity against the tuberculosis bacterium 
Mycobacterium tuberculosis. For instance, pseudopteroxazol 
(25) (Fig. 6), benzoxazole diterpene alkaloid from the gorgoni-
an coral Pseudopterogorgia elisabethae, inhibits the growth of 
this mycobacterium by 97% in a concentration of 12.5 μg/ml 
in the absence of toxic effects [71], while (+)-8-hydroxyman-
zamine (26) (Fig. 7) from the sponge Pachypellina sp [71] has a 
minimum inhibiting concentration of 0.91 μg/ml. Manzamine 
is even more active against the protozoa Toxoplasma gondii 
(Ic50=0.054 μg/ml), an infectious agent which causes such 
extremely dangerous (especially for pregnant women and 
children) diseases as toxoplasmosis. Manzamine is not used in 
medicine due to its low accessibility. 
Diterpenoid bromosphaerone (27) (Fig. 7) from the red alga 
Sphaerococcus coronopifolius (Ic50=0.078 μg/ml), dimeric 
isoquinoline alkaloid jorumicin (28) (Fig. 7) from the Pacific 
sea hare Jorunna funebris (Ic50=0.050 μg/ml), and some other 
marine metabolites [71] are highly active against Staphyloco-
ccus aureus. 
However, most of these substances, as well as fascalkaloid 
fascaplysin (29) (Fig. 7), macrolide forboxazole A (30) (Fig.7) 
and others characterized by strong antifungal action, have 
appeared too toxic for use in clinical testing. 
MARINE NATuRAL PRODuCTS WITh 
OThER BIOLOgICAL EFFECTS 
two new drugs – Histochrome for ophthalmology and His-
tochrome for cardiology –have been created in the Pacific 
Institute of Bioorganic chemistry, russian Academy of Sci-reVIeWS
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ences, on the basis of sea urchin pigments characterized by 
antioxidant, antimicrobial and anti-inflammatory proper-
ties and then approved for production and use in russia [74]. 
Histochrome for ophthalmology has proved highly effective 
against traumas and blood strokes of different origins and 
against some other eye diseases. Histochrome for cardiology 
is a cardioprotector reducing by half the necrosis zone formed 
due to acute myocardial infarction. Histochrome for cardiolo-
gy commonly assigned as drop infusion 10 minutes before the 
thrombolytic therapy decreases the frequency of extrasysto-
les. Moreover, this drug decreases the number of complica-
tions after open-heart surgery. the major constituent active 
substance of both drugs is the well-known pigment echinoc-
hrome (31) (Fig. 8). Scientists have found an easily accessible 
natural source of echinochrome (the sand dollar Scaphechi-
nus mirabilis) and have developed new methods of isolation 
and synthesis of this pigment with a high yield [47]. 
the clinical application of Histochrome drugs has demon-
strated their advantages relative to the analogous drugs used 
previously. the data obtained on the Histochrome for oph-
thalmology are of special interest. Histochrome for ophthal-
mology has been established to be successful in the treatment 
of hemophthalmos, different child eye pathologies, cataract, 
as well as in eye surgery. 
In 1971, a toxin called anabasein (32) (Fig. 8) was extracted 
from the sea worm hoplonemertea [75]. the synthesis of nu-
merous anabasein analogues has led to the creation of several 
highly active compounds, including the pharmaceutical lead 
GtS-21 (33) (Fig. 8), which has displayed cytoprotector prop-
erties and improved memory in test animals. competing with 
the natural ligands, GtS-21 binds to α4β and the α7-subtypes 
of nicotinic receptors; the latter is considered to be important 
in control of β-amyloid neurotoxicity. Florida State univer-
sity sold to the Japanese company taicho the license for those 
substances, and they have organized clinical testing in europe 
and the u.S. the first stages of testing on patients-volunteers 
showed the significant cognitive effects of GtS-21 [76]. cur-
rently, substances of this series are being studied as potential 
drugs for the treatment of Alzheimer’s disease. 
Holothurians (sea cucumbers), invertebrates belonging to 
the Holothurioidea class of the phylum echinodermata, have 
always attracted the attention of people in eastern Asian 
countries due to their biologically active substances. edible 
animals of that class (trepangs) are thought to have healing 
properties, including stimulation, wound-healing, and other 
23 Avarone 24  Mycalamide B
25 Pseudopteroxazol
26 8-Hydroxymanzamine
27 Bromosphaerone 28  Jorumycin
30 Phorboxazole A
29  Fascaplysin
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useful effects. However, the substances responsible for the 
biological activity of trepangs have yet to be studied. 
In the course of a multi-year investigation, scientists from 
the Pacific Institute of Bioorganic chemistry, russian Acad-
emy of Sciences, have collected about 50 species of holothuri-
ans in different parts of the World Ocean and obtained more 
than 100 new physiologically active triterpene glycosides 
from their extracts [76]. Some of them have turned out to be 
strong modulators of cellular immunity. these substances 
serve as a basis for the development of a potential drug called 
cumaside, which contains the agents (34, 35) (Fig. 8) as an ac-
tive substance [77]. this drug, in very low concentrations, in-
creases the resistance of test animals to bacterial infections 
and radiation, stimulates the phagocytic and bactericide ac-
tivities of macrophages, inhibits tumor growth and intensifies 
the action of antitumor drugs, without displaying any toxic 
properties [78, 79]. cumaside will be subjected to clinical test-
ing in the nearest future. 
CONCLuSION
Marine natural products are quite diverse. every year, the 
number of known marine natural products increases (be-
tween 2007 and 2008, almost by 1,000 compounds every year) 
[80]. their biochemical diversity is a result of the high bio-
logical diversity in the seas and oceans. According to different 
estimates, our planet is inhabited by several million species of 
marine microorganisms, as well as about a million of yet un-
described species of marine invertebrates and other marine 
organisms. 
the investigation of marine natural products has led to 
the creation of a series of highly efficiency medical products, 
including antitumor and antiviral drugs (Arabinocytosine, 
Arbinoadenosine, trabectidin), the analgesic drug Prialt, two 
russian drugs of the Histochrome series, which are able to 
decrease the necrosis zone after myocardial infarction and to 
treat the consequences of eye blood stroke of a different ethi-
ology, as well as the russian burn-treating drug collagenase 
KK. More than 40 antitumor, anti-inflammatory, immunos-
timulatory, and other pharmaceutical leads are at different 
stages of preclinical and clinical testing. this all became possi-
ble thanks to the physiological activity of some marine natu-
ral products. Among them are the most potent non-protein 
toxins (palytoxin, maitotoxin), the most effective inhibitors 
of tumor cells development (spongistatin, etc.), the strong-
est analgesic compounds (the toxins of cone snails), and other 
extremely active substances. 
It appears that many marine secondary metabolites ex-
tracted from sponges, ascidians, and other marine inverte-
brates are biosynthesized by symbiont microorganisms [80]. 
Only 1% of such microorganisms can grow in an artificial 
environment and may be cultivated. An example is the ex-
traction of the bacterium Micromonospora sp from the deep-
water sponge by American scientists. It produces manzamine 
and 8-hydroxymanzamine. As was mentioned before, these 
substances show very promising anti-parasitogenic and anti-
tuberculous activity, but they cannot be obtained in a large 
amount from the sponges. It is of interest that the biosyn-
thesis of physiologically active alkaloids in this bacterium is 
possible only in a special environment, while the standard 
cultivation is not appropriate for their formation [5]. re-
cently, Fenical and his co-workers selected a medium for the 
cultivation of marine microorganisms with regard to condi-
tions characteristic of their habitats. As a result, they have 
managed to cultivate a range of marine actinomycetes and 
to obtain a series of new secondary metabolites from them 
[81]. As follows from their investigation of the related spe-
cies belonging to the new class Salinispora, the biosynthesis 
of secondary metabolites in marine microorganisms is often 
not strain-specific, but species-specific, which makes these 
microorganisms an appropriate and reproducible source of 
highly active compounds. In the opinion of newman and oth-
er scientists from the national Institute of cancer (uSA), the 
study of bioactive substances from marine microorganisms 
has just begun [81].  
In recent years, a new direction in the search for and study 
of marine natural products – marine metagenomics – has 
appeared. Within the framework of this direction, not indi-
vidual genomes, but a group of genomes from any habitat, 
for instance from sponges, are analyzed and subjected to ma-
nipulations. In addition to the sponge genome, the genomes 
of numerous microorganisms, largely those hard to cultivate, 
are investigated. the transfer of big gene clusters to bacte-
ria which are easy to cultivate, followed by the analysis of 
the metabolite products in some clones, may lead to the crea-
tion of producers of useful compounds [82, 83]. However, it is 
essential to have knowledge about the biosynthesis of these 
substances to solve the problem of the creation of useful nat-
31 Echinochrome A 32 Anabasein
34 R=СH3 Cucumarioside А2-2
35 R=Н Cucumarioside А2-4
36 Psammaplin A
33 GTS-21
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ural products by this method. A while ago, scientists reported 
on the transcription of the genes responsible for the biosyn-
thesis of such highly active marine metabolites as bryostatins 
and some metabolites extracted from sponges [83, 84]. the 
metagenome projects are being realized now on vast water 
areas (Monterey Bay, the Sargasso Sea) [85]. 
Some marine organisms are characterized by high pro-
ductivity. For instance, the productivity of microalgae is 
higher than that of agricultural plants. they may be the 
sources not only of such useful for medicine substances as 
ω-3 fatty acids and carotenoids, but, likely, of other highly 
active compounds, as well as biofuel. It is necessary to select 
the most promising strains of these plants and to develop 
new-generation phytobioreactors to obtain biomass in an 
amount sufficient for the solution of these problems [86]. 
Finally, the study of biologically active marine natural com-
pounds stimulates work aimed at the organic synthesis of these 
compounds, as well as that of their derivatives and analogues. 
As a result, extensive libraries of compounds, including those 
characterized by a higher activity than a substance’s proto-
type, are created. For instance, in the course of the investiga-
tion of histone deacetylase inhibitors, the novartis company, 
in cooperation with the group of well-known chemist-synthe-
sist nikolaou, using the marine natural compound psammaplin 
A (36) (Fig. 8) as a prototype, obtained a library of 3,828 sub-
stances through organic synthesis; 6 of those substances were 
highly active against the methicillin- and vincamycin-resistant 
strains of Staphylococcus aureus [5].   
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